+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Melanoma. Critical Debates. Challenges In

  • ID: 2221501
  • Book
  • February 2002
  • Region: Global
  • 304 Pages
  • John Wiley and Sons Ltd
1 of 3
This book brings a new approach to the subject of melanoma, highlighting the current areas of controversy and debate. A wide spectrum, ranging from clinical investigation into the scientific basis of the disease through to its management and prognosis, is covered. In each section, al selection of controversial issues are discussed.

Internationally renowned experts critically appraise the literature and combine this with their own clinical and research experience to present an informed view of a range of issues. Arguments are therefore supported by the most recently available evidence. Melanoma: Critical Debates provides the reader with an up–to–date interpretation of the clinical trial data in this field and their relevance to daily practice.

Note: Product cover images may vary from those shown
2 of 3
Aetiology and Risk.

Chapter 1: What patterns of sun exposure really cause melanoma?.

Chapter 2: Are sunbeds dangerous?.

Chapter 3: Do sunscreens cause cancer or protect from a risk of melanoma?.

Chapter 4: Why are redheads so susceptible to melanoma?.

Chapter 5: How should we manage patients with atypical moles?.

Chapter 6: What should we know and what should we do about high–risk families?.

Chapter 7: How should we manage borderline melanocytic lesions?.

.

Diagnosis, Screening and Prevention.

Chapter 8: How can we improve early diagnosis?.

Chapter 9: What are the prospects for screening for melanoma at different latitudes?.

.

Management.

Chapter 10: What should we consider when excising the primary?.

Chapter 11: What imaging/investigation in melanoma patients?.

Chapter 12: What management for regional lymph node relapse?.

Chapter 13: What are the issues surrounding congenital naevi?.

Chapter 14: What is the role of chemotherapy?.

Chapter 15: What is the role of biological–response–modifiers in the treatment of melanoma?.

Chapter 16: Will vaccines really work for melanoma?.

Chapter 17: Who should we consider for isolated limb perfusion?.

Chapter 18: What are the novel treatment strategies are on the horizon?.

Chapter 19: Who should follow–up melanoma patients and for how long?.

Chapter 20: What is the role for radiotherapy in melanoma?.

Chapter 21: What should we tell patients about hormones after having melanoma?

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Julia A. Newton Bishop
Martin Gore
Note: Product cover images may vary from those shown
Adroll
adroll